Abbott India Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Abbott India Ltd is ₹ 25430 as of 30 Apr 15:30 . The P/E Ratio of Abbott India Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Abbott India Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Abbott India Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Abbott India Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Abbott India Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The Dividend Payout of Abbott India Ltd changed from 84.61 % on March 2021 to 0 % on December 2025 . This represents a CAGR of -100.00% over 10 yearsThe Dividend Payout of Sanofi India Ltd changed from 119.34 % on December 2021 to 86.59 % on December 2025 . This represents a CAGR of -6.21% over 5 years .

About Abbott India Ltd

Abbott India Limited was originally incorporated on August 22, 1944 as Boots Pure Drug Company (India) Limited.
The company name was changed to 'The Boots Company (India) Limited' on November 1, 1971, thereafter to Boots Pharmaceuticals Limited on January 1, 1991.
In October, 1995 the name was changed to Knoll Pharmaceuticals Limited, and in July, 2002, they got their present name 'Abbott India Limited'. Company is one of the leading multinational pharmaceutical companies in India and operates with an owned manufacturing facility in Goa and various independent contract/third party manufacturers based across the country.
The Company sells its products through independent distributors primarily within India.
It provides products and solutions across various therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, Consumer Health, etc.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Abbott India Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Abbott India Ltd or Sanofi India Ltd?

Market cap of Abbott India Ltd is 54,040 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Abbott India Ltd and Sanofi India Ltd?

The stock performance of Abbott India Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Abbott India Ltd and Sanofi India Ltd?

As of May 4, 2026, the Abbott India Ltd stock price is INR ₹25430.9. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Abbott India Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Abbott India Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.